An in vivo screen identifies NAT10 as a master regulator of brain metastasis
Science Advances · 2025
DOI: 10.1126/sciadv.ads6021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Jocelyn F Chen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, N-Terminal Acetyltransferase E, Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Emerging evidence has shown that epigenetic regulation plays a fundamental role in cancer metastasis, the major cause of cancer-related deaths. Here, we conducted an in vivo screen for vulnerabilities of brain metastasis and identified N -acetyltransferase 10 (NAT10) as a driver of brain metastasis. Knockdown of NAT10 restrains cancer cell proliferation and migration in vitro and tumor growth and brain metastasis in vivo. The poorly characterized RNA helicase domain of NAT10 is critical for cell growth in vitro, while both RNA helicase and NAT domains are essential for primary tumor growth and brain metastasis in vivo. Mechanically, NAT10 promotes the expression of 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT1), two enzymes for serine biosynthesis implicated in brain metastasis. Silencing PHGDH or PSAT1 in metastatic breast cancer cells inhibits their growth in the serine/glycine-limited condition, phenocopying the effects of NAT10 depletion. These findings establish NAT10 as a key regulator of brain metastasis and nominate NAT10 as a target for treating metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
- Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT 06510, USA.
- Systems Biology Institute, Yale West Campus, West Haven, CT 06516, USA.
- Department of Pharmacology, Yale Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
- Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA.
- Department of Internal Medicine (Section of Hematology), Yale School of Medicine, New Haven, CT 06520, USA.
ORCID-Profile: Jocelyn F Chen, Peng Xu, Wesley L Cai, Huacui Chen, Xiaojian Shi, Wenxue Li, Giulia Biancon, Meiling Zhang, Amer Balabaki, Yangyi Zhang, Mingzhu Yin, Toma Tebaldi, Jordan L Meier, Stephanie Halene, Yansheng Liu, Hongying Shen, Don X Nguyen, Qin Yan
Förderung
- NCI NIH HHS
Zitieren
APA
Chen, J. F., Xu, P., Cai, W. L., Chen, H., Wingrove, E., Shi, X., Li, W., Biancon, G., Zhang, M., Balabaki, A., Krop, E. D., Asare, E., Zhang, Y., Yin, M., Tebaldi, T., Meier, J. L., Westbrook, T. F., Halene, S., Liu, Y., …, & Yan, Q. (2025). An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Science Advances. https://doi.org/10.1126/sciadv.ads6021
Vancouver
Chen JF, Xu P, Cai WL, Chen H, Wingrove E, Shi X, et al. An in vivo screen identifies NAT10 as a master regulator of brain metastasis. Science Advances. 2025. doi:10.1126/sciadv.ads6021
BibTeX
@article{Chen2025,
author = {Chen, Jocelyn F and Xu, Peng and Cai, Wesley L and Chen, Huacui and Wingrove, Emily and Shi, Xiaojian and Li, Wenxue and Biancon, Giulia and Zhang, Meiling and Balabaki, Amer and Krop, Ethan D and Asare, Elianna and Zhang, Yangyi and Yin, Mingzhu and Tebaldi, Toma and Meier, Jordan L and Westbrook, Thomas F and Halene, Stephanie and Liu, Yansheng and Shen, Hongying and Nguyen, Don X and Yan, Qin},
title = {An in vivo screen identifies NAT10 as a master regulator of brain metastasis},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ads6021}
}
EUVIMED